Hayashi M, Floyd J C, Pek S, Fajans S S
J Clin Endocrinol Metab. 1977 Apr;44(4):681-94. doi: 10.1210/jcem-44-4-681.
Insulin, proinsulin, glucagon and gastrin were determined in extracts of tumors of 27 patients with pancreatic islet cell neoplasia of pancreas, in one patient with nesidioblastosis, in extracts of uninvolved portions of the pancreas in 11 of the tumor patients and of 15 control pancreases. Mean insulin concentration in solitary adenomas and in adenomas of patients with adenomatosis was higher than in control pancreases; however, in all but 1 patient the insulin concentration in neoplastic islet tissue was lower than in islet tissue of control pancreas, assuming islet volume is 1% of pancreas. The percentage of proinsulin was elevated in 52% of tumors. Adenoma insulin content correlated with increments of plasma insulin after tolbutamide administration. Insulin and proinsulin concentrations in pancreas uninvolved by tumor were not suppressed. Fasting plasma glucagon was elevated in patients with islet cell adenomatosis and in patients with islet cell carcinoma some of whom had multiple endocrine adenomatosis. The mean concentration of glucagon in tumors was lower than in control pancreases. Elevated concentration of gastrin was found in some adenomas. The data indicate: 1) insulin-secreting islet cell tumors have decreased storage capacity for insulin, 2) elevated concentration of proinsulin in tumors may be due to decreased capacity to store insulin and in some to decreased conversion of proinsulin to insulin as well, 3) tolbutamide stimulates the exaggerated release of a relatively constant fraction of insulin stored in adenomas. 4) solitary adenomas may contain excess amounts of pancreatic hormones in addition to insulin, 5) elevated plasma glucagon in patients with organic hyperinsulinism may indicate malignancy, microadenomatosis or multiple endocrine adenoma syndrome, and 6) chronic hyperinsulinism and hypoglycemia due to adenoma do not suppress insulin and proinsulin content of uninvolved pancreas.
对27例胰腺胰岛细胞瘤、1例胰岛细胞增殖症患者肿瘤提取物,以及11例肿瘤患者和15例对照胰腺未受累部分的提取物进行了胰岛素、胰岛素原、胰高血糖素和胃泌素测定。孤立性腺瘤和腺瘤病患者腺瘤中的胰岛素平均浓度高于对照胰腺;然而,除1例患者外,假设胰岛体积占胰腺的1%,肿瘤性胰岛组织中的胰岛素浓度低于对照胰腺的胰岛组织。52%的肿瘤中胰岛素原百分比升高。腺瘤胰岛素含量与服用甲苯磺丁脲后血浆胰岛素的增加相关。肿瘤未累及的胰腺中胰岛素和胰岛素原浓度未被抑制。胰岛细胞腺瘤病患者和部分患有多发性内分泌腺瘤病的胰岛细胞癌患者空腹血浆胰高血糖素升高。肿瘤中胰高血糖素的平均浓度低于对照胰腺。在一些腺瘤中发现胃泌素浓度升高。数据表明:1)分泌胰岛素的胰岛细胞瘤胰岛素储存能力下降;2)肿瘤中胰岛素原浓度升高可能是由于胰岛素储存能力下降,部分也是由于胰岛素原向胰岛素的转化减少;3)甲苯磺丁脲刺激腺瘤中储存的相对恒定比例的胰岛素过度释放;4)孤立性腺瘤除胰岛素外可能还含有过量的胰腺激素;5)器质性高胰岛素血症患者血浆胰高血糖素升高可能表明恶性肿瘤、微腺瘤病或多发性内分泌腺瘤综合征;6)腺瘤引起的慢性高胰岛素血症和低血糖症不会抑制未受累胰腺的胰岛素和胰岛素原含量。